Early Data Presented At ASCO Show Potential Of RAD001 To Enhance Efficacy Of, And Ove
Early proof-of-concept studies presented today show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments.Findings from a Phase II study show that RAD001 enhances tumour shrinkage when given in combination with letrozole (Femara®) to postmenopausal women with newly diagnosed oestrogen receptor-positive (ER+) breast cancer.
More... |
All times are GMT -7. The time now is 10:01 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021